Welcome to our dedicated page for Arcturus Therape news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therape stock.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is a San Diego-based commercial mRNA medicines and vaccines company focused on liver and respiratory rare disease therapeutics and infectious disease vaccines. News about Arcturus often centers on clinical trial progress, regulatory interactions and collaboration updates linked to its LUNAR® lipid-mediated delivery and STARR® self-amplifying mRNA (sa-mRNA) platforms.
Investors following ARCT news can expect regular updates on the companys RNA therapeutic candidates for ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), including interim data from Phase 1 and Phase 2 studies, safety and tolerability findings, biomarker changes and plans for longer-duration or pivotal trials. Disclosures have highlighted programs such as ARCT-032, an inhaled mRNA therapy for CF, and ARCT-810, an mRNA therapeutic candidate for OTC deficiency.
Arcturus also issues frequent announcements related to its infectious disease vaccine portfolio. These include developments for KOSTAIVE®, described as the first approved self-amplifying mRNA COVID-19 vaccine, along with sa-mRNA influenza candidates like ARCT-2138 and pandemic influenza A H5N1 candidate ARCT-2304. News items may cover Phase 1 or Phase 3 data, immunogenicity and safety results, and regulatory submissions or approvals in collaboration with CSL Seqirus and partners such as Meiji Seika Pharma.
Additional ARCT headlines often involve financial results, cash runway commentary, cost management actions, investor conference participation and SEC filings that provide corporate updates. Stock Titans ARCT news page aggregates these company press releases, regulatory disclosures and related coverage so readers can track how Arcturus clinical, regulatory and partnership milestones may influence sentiment around ARCT stock over time.
Arcturus Therapeutics (Nasdaq: ARCT) announced that Joseph Payne, President & CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026 at 5:15 p.m. Pacific Time. The company is a commercial messenger RNA medicines company focused on liver and respiratory rare disease therapeutics and infectious disease vaccines.
Arcturus Therapeutics (Nasdaq: ARCT) will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 12:30 p.m. ET.
The company is a commercial messenger RNA medicines company focused on liver and respiratory rare disease therapeutics and infectious disease vaccines.
Arcturus Therapeutics (Nasdaq: ARCT) reported Q3 2025 results and program updates on November 10, 2025. Revenue for Q3 was $17.2M and $74.8M for the nine months, declines of $24.5M and $54.7M year-over-year driven by lower CSL collaboration activity. Operating expenses were $33.7M in Q3 (down from $52.4M). Net loss for Q3 was $13.5M or ($0.49) per diluted share; nine-month net loss was $36.7M.
Clinical: interim Phase 2 ARCT-032 CF data showed mucus-burden reductions in 4 of 6 Class I participants; a 12-week, up-to-20-participant study is planned for H1 2026. Cash and equivalents were $237.3M with runway extended into 2028 after Q4 cost reductions.
Arcturus Therapeutics (Nasdaq: ARCT) will participate in two investor events in November 2025: a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 11:30 a.m. ET, and one-on-one meetings at the Jefferies Global Healthcare Conference in London from November 17–20, 2025 (GMT). The appearances provide scheduled opportunities for investor engagement and updates on the company’s commercial mRNA programs in liver, respiratory rare diseases, and infectious disease vaccines.
Arcturus Therapeutics (Nasdaq: ARCT) will release its third quarter 2025 financial results after the market close on Monday, November 10, 2025.
The company will host a conference call and webcast on November 10, 2025 at 4:30 p.m. ET. Domestic dial-in is 1-800-274-8461, international dial-in is 1-203-518-9814, and the conference ID is ARCTURUS. A webcast link will be provided for live listening.
Arcturus (Nasdaq: ARCT) reported interim Phase 2 results for inhaled mRNA therapy ARCT-032 in Class I cystic fibrosis patients.
In a 28-day, 10 mg cohort (6 adults) the treatment was generally safe and well tolerated; one SAE occurred well after dosing that a Data Monitoring Committee found no convincing evidence of product relatedness. AI-enhanced HRCT showed mucus plug and mucus volume reductions in 4 of 6 participants (largest mucus volume drop −67.4%). A post hoc exploratory analysis showed average ppFEV1 +3.8% absolute (+5.1% relative) in 4 of 6 participants vs pre-treatment baseline. A 12-week safety and preliminary efficacy study enrolling up to 20 participants is planned for H1 2026; an ongoing 15 mg cohort is enrolling to evaluate dose response.
Arcturus Therapeutics (NASDAQ:ARCT), a commercial mRNA medicines company specializing in liver and respiratory rare disease therapeutics and infectious disease vaccines, has announced its participation in four upcoming investor conferences in September 2025.
The company will participate in fireside chats at Citi's Biopharma Back to School Conference (Sept 2), Wells Fargo Healthcare Conference (Sept 3), and Cantor Global Healthcare Conference (Sept 5). Additionally, Arcturus will deliver a presentation at the H.C. Wainwright Global Investment Conference (Sept 9).
Arcturus Therapeutics (NASDAQ:ARCT) reported Q2 2025 financial results and pipeline updates. Key highlights include: Q2 revenue of $28.3M (down from $49.9M in Q2 2024) and net loss of $9.2M ($0.34 per share). The company maintains a strong cash position of $253.4M, extending runway into 2028.
Pipeline progress includes: Cystic fibrosis (ARCT-032) Phase 2 interim data from nine participants expected September 2025; OTC deficiency (ARCT-810) showed positive Phase 2 results with Phase 3 planning in H1 2026; KOSTAIVE® regulatory submissions advancing globally; and Seasonal flu vaccine (ARCT-2138) demonstrated positive Phase 1 results in both young and older adults.
Arcturus Therapeutics (NASDAQ:ARCT), a commercial mRNA medicines company specializing in infectious disease vaccines and rare diseases, has scheduled its second quarter 2025 financial results announcement. The company will release its Q2 results on Monday, August 11, 2025, after market close.
A conference call and webcast will follow at 4:30 PM Eastern Time the same day. Investors can access the call via domestic (1-800-274-8461) or international (1-203-518-9814) numbers using the conference ID "ARCTURUS".
Arcturus Therapeutics (NASDAQ:ARCT), a commercial mRNA medicines company specializing in infectious disease vaccines and rare diseases, has announced its participation in two upcoming investor conferences.
The company will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on July 29, 2025, at 12:40 p.m. ET, and deliver a presentation at the CG 45th Annual Growth Conference on August 12, 2025, at 8:30 a.m. ET.
FAQ
What is the current stock price of Arcturus Therape (ARCT)?
What is the market cap of Arcturus Therape (ARCT)?
